Market Overview

Goodwin Boosts Life Sciences Capabilities in Northern California with Partner Shane Albright in Silicon Valley

Share:

Global law firm Goodwin announced today that Shane
Albright
has joined the firm's Silicon
Valley
office as partner in its Life
Sciences
practice, expanding the firm's resources and offering in
Northern California.

Albright represents life science companies in a wide range of corporate,
financial and commercial matters, with a particular emphasis on complex
transactions involving intellectual property. He has extensive
experience counseling clients on corporate partnering issues, strategic
alliances, technology licenses and key commercial contracts, such as
manufacturing and distribution agreements. Albright also represents
emerging growth companies and their investors in venture financings,
other funding transactions and general corporate matters. His clients
include companies in the biopharmaceutical, medical device, diagnostics,
hardware, software, medical instrumentation, digital health, vaccine and
research reagent spaces, as well as entities that fund or conduct
medical research.

"Goodwin has developed a leading international life sciences practice,
which cutting-edge biotech companies continually engage to help guide
them through formation to strategic collaborations and exits, and
everything in between," said Mitchell
Bloom
, Co-Chair of Goodwin's Life Sciences Practice. "Shane's vast
experience handling complex licensing transactions, mergers and
acquisitions, and initial public offerings complements our existing
bench and expansion efforts on the West Coast. We are thrilled that he
has chosen to join our firm."

Albright said, "Goodwin has a well-deserved reputation for handling some
of the most complex and innovative transactions in the life sciences
space. I am excited to join the team and looking forward to leveraging
the Goodwin platform to help my clients develop and monetize their
cutting-edge drugs and medical technologies."

Albright received his J.D. from Stanford University Law School and his
Ph.D. in Molecular and Cell Biology from the University of California,
Berkeley. He is admitted to practice in California and has been
recognized as a "Life Sciences Star" by LMG Life Sciences.
Albright is also a frequent speaker on issues relating to licensing and
corporate partnering.

He can be reached at salbright@goodwinlaw.com
and on 650.752 3219.

Goodwin's Life Sciences practice was named "Practice
Group of the Year
" for the past two years by Law360, which
called Goodwin "a top choice for high-profile pharmaceutical clients,
particularly in licensing deals, mergers and acquisitions, and initial
public offerings." The firm has also been recognized by U.S. News and
World Report - Best Lawyers
as "Biotech
Firm of Year
" for five out of last six years and as the "2017
IP Law Firm of the Year
" by LMG Life Sciences.

In 2018 to date, Goodwin
has represented
fifteen biotechnology companies on their public
offerings with a collective value close to $1.5 billion.

About Goodwin
At Goodwin, we use law to achieve
unprecedented results for our clients. Our 1,000 plus lawyers across the
United States, Europe, and Asia excel at complex transactions,
high-stakes litigations and world-class advisory services in the
financial, private equity, real estate, and technology industries. We
partner with our life sciences clients to practice law with integrity,
ingenuity, agility and ambition. To learn more, visit us at www.goodwinlaw.com
and follow us on Twitter, LinkedIn and Instagram.

View Comments and Join the Discussion!